BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
BioXcel Therapeutics (BTAI) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, which focuses on developing AI-driven neuroscience medicines, had received a non-compliance notice on September 16, 2024, after failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. To meet Nasdaq's Listing Rule 5550(a)(2), BTAI was required to maintain a minimum closing bid price of $1.00 per share for at least 12 consecutive trading days, which it achieved on February 26, 2025.
BioXcel Therapeutics (BTAI) ha riconquistato con successo la conformità ai requisiti di prezzo minimo delle azioni di Nasdaq. L'azienda, che si concentra sullo sviluppo di farmaci neuroscientifici basati sull'IA, aveva ricevuto una notifica di non conformità il 16 settembre 2024, dopo non essere riuscita a mantenere un prezzo di chiusura minimo di $1.00 per azione per 30 giorni lavorativi consecutivi. Per soddisfare la Regola di Quotazione 5550(a)(2) di Nasdaq, BTAI doveva mantenere un prezzo di chiusura minimo di $1.00 per azione per almeno 12 giorni di negoziazione consecutivi, obiettivo che ha raggiunto il 26 febbraio 2025.
BioXcel Therapeutics (BTAI) ha recuperado con éxito el cumplimiento del requisito de precio mínimo de oferta de Nasdaq. La empresa, que se centra en el desarrollo de medicamentos de neurociencia impulsados por IA, había recibido un aviso de incumplimiento el 16 de septiembre de 2024, tras no poder mantener un precio de oferta de cierre mínimo de $1.00 por acción durante 30 días hábiles consecutivos. Para cumplir con la Regla de Cotización 5550(a)(2) de Nasdaq, BTAI debía mantener un precio de oferta de cierre mínimo de $1.00 por acción durante al menos 12 días de negociación consecutivos, lo cual logró el 26 de febrero de 2025.
BioXcel Therapeutics (BTAI)는 Nasdaq의 최소 입찰 가격 요건을 성공적으로 회복했습니다. 인공지능 기반의 신경과학 의약품 개발에 중점을 둔 이 회사는 2024년 9월 16일에 최소 30 영업일 동안 주당 $1.00의 최소 종가를 유지하지 못한 후 비준수 통지를 받았습니다. Nasdaq의 상장 규칙 5550(a)(2)를 준수하기 위해 BTAI는 최소 12일 연속 거래일 동안 주당 $1.00의 최소 종가를 유지해야 했으며, 이는 2025년 2월 26일에 달성했습니다.
BioXcel Therapeutics (BTAI) a réussi à retrouver la conformité avec l'exigence de prix d'offre minimum de Nasdaq. L'entreprise, qui se concentre sur le développement de médicaments en neurosciences alimentés par l'IA, avait reçu un avis de non-conformité le 16 septembre 2024, après avoir échoué à maintenir un prix d'offre de clôture minimum de $1.00 par action pendant 30 jours ouvrables consécutifs. Pour répondre à la règle de cotation 5550(a)(2) de Nasdaq, BTAI devait maintenir un prix d'offre de clôture minimum de $1.00 par action pendant au moins 12 jours de négociation consécutifs, ce qu'elle a réalisé le 26 février 2025.
BioXcel Therapeutics (BTAI) hat erfolgreich die Einhaltung der Mindestangebotspreisanforderungen von Nasdaq wiederhergestellt. Das Unternehmen, das sich auf die Entwicklung von KI-gesteuerten Neurowissenschaftsmedikamenten konzentriert, hatte am 16. September 2024 eine Mitteilung über die Nichteinhaltung erhalten, nachdem es nicht in der Lage war, einen Mindestschlusskurs von $1.00 pro Aktie für 30 aufeinanderfolgende Handelstage aufrechtzuerhalten. Um die Nasdaq-Listing-Regel 5550(a)(2) zu erfüllen, musste BTAI einen Mindestschlusskurs von $1.00 pro Aktie für mindestens 12 aufeinanderfolgende Handelstage aufrechterhalten, was am 26. Februar 2025 gelang.
- Regained Nasdaq listing compliance, removing delisting risk
- Stock previously traded below $1.00 for extended period, indicating significant market weakness
NEW HAVEN, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2).
As previously disclosed, on September 16, 2024, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum closing bid price of
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.
Contact Information
Corporate/Investors
BioXcel Therapeutics
Erik Kopp
1.203.494.7062
Media
Russo Partners
David Schull
1.858.717.2310
Source: BioXcel Therapeutics, Inc.
FAQ
When did BioXcel Therapeutics (BTAI) regain Nasdaq compliance?
Why was BTAI stock initially flagged for Nasdaq non-compliance?
What were the requirements for BTAI to regain Nasdaq compliance?
How long was BTAI out of compliance with Nasdaq's minimum bid price rule?
